Omeprazole and CYP2C19 polymorphism: Effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 11, 2000, Pages 1495-1502

  Sagar, M ^a,b,c,d,e,f   Bertilsson, L ^a,b,c,d,e,f   Stridsberg, M ^a,b,c,d,e,f   Kjellin, A ^a,b,c,d,e,f   Mardh S ^a,b,c,d,e,f   Seensalu, R ^a,b,c,d,e,f  

^a Clinical Research Center   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ERSTA HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CYTOCHROME P450 2C19; GASTRIN; OMEPRAZOLE; PEPSINOGEN I;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMOGRANIN A; CHROMOGRANINS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PEPSINOGEN A; PEPTIC ULCER; POLYMORPHISM, GENETIC; RADIOIMMUNOASSAY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033694865     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00835.x     Document Type: Article

References (50)

1. Omeprazole. An update of its pharmacology and therapeutic use in acid related disorders
2. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
3. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
4. Pharmacokinetics and metabolism of omeprazole in man
5. Omeprazole: Pharmacokinetics and metabolism in man
6. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
7. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from Oriental population
8. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population
9. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
10. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population?
11. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
12. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
13. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
14. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid related disorders with and without H. pylori infection
15. The diffuse endocrineparacrine system of the gut in health and disease: Ultrastructural features
16. Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas or intestines in hamster, guinea pig and chicken
17. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats
18. ECL cell proliferation and gastrin level
19. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa
20. Circulating gastrim endocrine cells, histamine content, and histidine decarboxylase activity in atrophic gastritis
21. Gastric endocrine cell proliferation. Association with Zollinger-Ellison syndrome
22. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association
23. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmuno-assay for chromogranin A and its fragments
24. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours
25. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients
26. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis
27. Marked increase in gastric acid secretory capacity after omeprazole treatment
28. Twenty-four-hour intragastric pH, basal and meal-stimulated serum gastrin, and plasma chromogranin A after short-term acid inhibition
29. Serum pepsinogen I and serum gastrin in the secreening of severe atrophic corpus gastritis
30. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels
31. 12 in patients on long-term omeprazole treatment
32. Serum gastrin determination with a radioimmunosorbent technique
33. Helicobacter pylori in 205 consecutive endoscopy patients
34. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age
35. Inter phenotype differences in disposition and effect on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19
36. The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related disease
37. CYP2C19 genotype status and effect of omeprazole
38. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion
39. Long-term omeprazole treatment in man: Effects on gastric endocrine cell populations
40. Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine
41. Gastric mucosa during treatment with lanzoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
42. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lanzoprazole
43. Lanzoprazole. H. pylori, and atrophic gastritis
44. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundiplication
45. Long-term sequelae of Helicobacter pylori gastritis
46. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-time safety
47. Effect of short-term omeprazole administraion on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion
48. Effect of short-term administration of omeprazole on serum gastrin and pepsinogens in antrectomized patients
49. Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C
50. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis